New Clinical Trials Available at FHCI

Doctor in hallway at AdventHealth Orlando
Choose the health content that's right for you, and get it delivered right in your inbox

Alliance A221505: Phase III randomized trial of hypofractionated post-mastectomy radiation with breast reconstruction

CBYL719X2402: A Phase II, multi-center, open-label, two-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone-receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after CDK 4/6 inhibitor treatment

SPI-QAP-306: A randomized, multi-center, two-arm, single-dose, double-blind, placebo-controlled Phase III study of intravesical Qapzola (apaziquone) as a chemotherapy adjuvant to transurethral Resection of bladder tumors in patients with low- to intermediate-risk non-muscle invasive bladder cancer (CONQUER)

7465-CL-0301: An open-label, randomized Phase III study to evaluate enfortumab vedotin vs. chemotherapy in subjects with previously treated locally advanced or metastatic urothelial cancer

GU006: A Phase II, double-blinded, placebo-controlled randomized trial of salvage radiotherapy with or without enhanced anti-androgen therapy with apalutamide in recurrent prostate cancer

Clovis/GOG 3020: A multi-center, randomized, double-blind, placebo-controlled Phase III study of rucaparib in combination with nivolumab versus placebo as switch maintenance following response to front-line platinum-based chemotherapy in patients with high-grade serous or endometrioid epithelial ovarian, primary peritoneal or fallopian tube cancer

MK3475-775: A multi-center, open-label, randomized, Phase III trial to compare the efficacy and safety of lenvatinib in combination with pembrolizumab versus treatment of physicians choice in participants with advanced endometrial cancer

JZP963-201: A Phase II, prospective, randomized, open-label study on the efficacy of defibrotide added to standard-of-care immunoprophylaxis for the prevention of acute graft-versus-host-disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant

MK3475-598: A Phase III, randomized, double-blind study of pembrolizumab plus ipilimumab vs pembrolizumab plus placebo in previously untreated, advanced/recurrent non-small cell lung cancer subjects whose tumors are PD-L1 positive (TPS 50%)

GRN-1201-002: Phase II study of GRN-1201 added to pembrolizumab in subjects with PD-L1+ non-small cell lung cancer

MM-398-01-03-04: A randomized, open-label, Phase III study of irinotecan liposome injection (ONIVYDE) versus topotecan in patients with small cell lung cancer who have progressed on or after platinum-based first-line therapy (RESILIENT)

For more information or to refer a patient, call the Clinical Research Office at Call407-303-7302. Eligibility criteria may also be viewed at

Recent Blogs

A Doctor Examines a Patient's Information on a Monitor During a Procedure
Ambulatory Surgery Center or Hospital Operating Room? Here’s What to Know
Three Colleagues Sit Outside Enjoying Lunch in the City.
Navigating Social Situations After Bariatric Surgery
Tackling Tough Topics With Your Kids
A Mother and Son sit on an Exam Table While They Speak to a Physician
Let Our Women’s and Children’s Health Navigators Be Your Guides
Honoring Cancer Heroes at Kansas Speedway
View More Articles